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In excess of 1 million people suffer from burns in Africa annually. [1] 
Across the African continent, burns account for 18% of hospital 
admissions and have a mortality rate of 6 - 10%.[1] According to 
a 2017 Medical Research Council report,[2] South Africa (SA)’s 
annual burn mortality rate of 8.5/100 000 is substantially above the 
world average of 5/100 000. The same report stated that 3% of the 
SA population suffer from burns annually, and that of these burns, 
20% are classified as moderate to severe. Moreover, ~161 children 
are severely burned in accidents in the home every month in SA, 
and because of inadequacies in the burn care system, 6 of these 
children will die. A World Health Organization report on burns in 
March 2018[3] claimed that annually in SA, USD26 million is spent 
on burn care for patients burned in cooking incidents from kerosene 
(paraffin) stoves.[3] The socioeconomic impact of this situation is 
worsened by indirect costs due to inability of these patients to return 
to work, resulting in their requiring disability grants, and their need 
for prolonged care for deformities caused by the burns.
Defining the problem
From the point of initial injury and throughout rehabilitation, the 
management of pain in burn patients is an area of major concern, 
with several clinicians attesting to burn pain being the most 
difficult of any of the acute pain aetiologies to treat.[4] In addition 
to pain related to the burn, the curative and rehabilitative therapies 
compound the difficulty of pain control, as these interventions, 
which include dressing changes, excision and grafting, and physical 
therapy, cause pain that is often equivalent to or worse than the 
pain of the initial burn injury.[4] Studies have shown that good pain 
management and control is associated with better wound healing, 
sleep, participation in activities of daily living, quality of life and 
recovery.[5,6] For the above reasons, pain management forms the 
foundation of burn care.
The benefits of ketamine are numerous. Since its first clinical use 
in 1970, ketamine has continued to remain a critical component 
of the medical arsenal of anaesthesiologists and clinicians treating 
both acute and chronic pain, in particular finding a growing use 
in the management of adult and paediatric burns.[7] Over the 
past two decades, several studies have investigated the additional 
antidepressant and anti-inflammatory effects of ketamine.[7-9] The 
appeal of ketamine in the clinical setting is its versatility as a result 
of its unique ability to induce three clinical outcomes, i.e. narcosis, 
analgesia and amnesia. There is currently no other medicine used in 
clinical practice that can provide these three effects simultaneously.[7] 
Apart from its rapid onset of action, it does not induce hypotension 
and there is minimal risk of airway loss because the pharyngeal and 
laryngeal reflexes are only slightly impaired. It also rarely induces 
bronchospasm, which makes it particularly useful in asthmatic 
patients as well as in children. Its increasing portfolio of use coupled 
with its safety profile have cemented its place in a plethora of 
management protocols in the South African Standard Treatment 
Guidelines.[10,11]
In the operating theatre, ketamine can be used for the induction 
and maintenance of anaesthesia. Because it does not induce 
hypotension, it is especially useful in cases where haemodynamic 
control is required.[12] Ketamine is also used in various settings 
outside the operating room, such as procedural sedation for dressing 
changes, splinting, line changes and fracture reductions. Ketamine 
shortages therefore pose a threat to doctors and patients alike in the 
SA healthcare system, demanding national attention from all those 
practising in the field.
The impact of ketamine shortages is far reaching, as this drug is 
the safest, most practical option for procedural sedation for minor 
procedures in wards and outpatient departments in hospitals with 
either no theatre facilities or limited theatre time. When it is not 
possible to do simple procedures safely in the ward, they need to be 
done in theatre. Theatre time is a scarce and costly resource in our 
environment.
This dilemma ultimately affects the quality of patient care, as 
every situation in which ketamine is out of stock has a measurable 
human impact. From the perspective of patients and their families, 
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medicine shortages result in wasted time and work days, money lost 
on pointless travel, poor retention and follow-up for chronic diseases, 
untreated diseases, and most importantly a loss of confidence in the 
public health system.[13]
At the bedside, doctors’ frustration due to medicine shortages is 
shared by pharmacists, who are required to make complex decisions 
and provide recommendations to doctors based on a limited 
availability of options. The failing balance of supply (pharmacist) 
and demand (doctor) often results in strained relationships between 
these two members of the healthcare team in the clinical setting. 
Hospital pharmacists are required to find alternatives, leading 
to the administration of second- and third-line medicines that 
may be inferior in quality or outcome. In the case of ketamine 
specifically, alternative treatments may not be readily available and 
in addition may require additional training and resources for their 
safe use. Alternative regimens further raise the risk of dosage errors 
if healthcare practitioners are not familiar with the dosing and 
administration required for these products. This lack of training and 
knowledge associated with using alternatives leads to adverse effects, 
unforeseen complications, and effectiveness issues that negatively 
affect costs and place an added strain on an already overburdened 
healthcare budget. From a clinical and ethical standpoint, shortages 
of a medicine like ketamine, which has multiple indications in the 
healthcare sector, require tough decisions to be made on which 
patient populations will be given priority for a medicine that is in 
short supply.
Alternatives to ketamine
One potential alternative to ketamine is methoxyflurane. It is a 
short-acting inhalational analgesic agent with a rapid onset of 
action. The analgesic effects manifest after 6 - 8 breaths, and once 
inhalation is ceased, the analgesic effects wear off within a few 
minutes. It has been well described in the management of acute pain 
and a variety of procedures including dressing changes and dental 
procedures. Although studies in the adult population predominate, 
there are studies proving it to be safe and efficacious in the paediatric 
population with minimal side-effects.[14] One of the disadvantages 
of methoxyflurane is that it is currently not widely available in the 
public health sector. It is more expensive than ketamine, and the 
majority of doctors are reluctant to use medications that they are 
unfamiliar with, which also limits its use.
Other alternatives for procedural sedation, such as the combination 
of propofol and fentanyl, are also limited by lack of availability in 
certain state facilities. The safety of such combinations in the hands 
of healthcare workers inexperienced in procedural sedation, and 
in view of the lack of monitoring equipment in these facilities, is 
questionable.
Why is there a ketamine shortage?
The reasons for the ketamine shortage are not entirely clear. Some of 
the global reasons provided by manufacturers include an increased 
demand for ketamine and manufacturing delays. There are currently 
only two registered ketamine products on the SA market (both of 
which are generics), which further contributes to the lack of a viable 
supply chain. In general, generic injectable medications are most 
commonly affected by shortages, owing to the costly and complex 
production processes related to their manufacture and the fact that 
they have smaller profit margins than branded medications, so there 
is a lack of interest on the part of manufacturers in producing the 
line. Furthermore, backlogs at the South African Health Products 
Regulatory Authority with regard to both new medicine and generic 
medicine registration limit the available alternatives.
In addition to manufacturing issues related to ketamine shortages, 
logistics and supply chain challenges are contributing factors. 
Maintaining an adequate inventory in the midst of a drug shortage is 
a difficult task, leading some providers and organisations to stock up 
on medicines in anticipation of a shortage, which increases costs and 
risks wasted inventory.[12] While the National Department of Health 
is aware of the problem, and there have been several studies attesting 
to medicine shortages, it is evident that procurement and distribution 
of medical supplies remain inadequate in SA.[15] Supply issues have 
also been linked to inadequate training and the inability of personnel 
to manage medicine supplies, report shortages, and respond 
appropriately to prevent their recurrence.[16] Additionally, challenges 
in the healthcare system related to shortages of healthcare workers, 
weak oversight and management, and inadequate monitoring and 
evaluation of clinical data have been reported as further contributing 
factors.
Conclusions
In a nutshell, ketamine is exceptionally user-friendly for relatively 
untrained clinicians in resource-limited settings, and any shortage of 
this drug should therefore be grounds for grave concern. Although 
there are a small number of alternatives to ketamine for the 
management of burn pain, the viability of these options in the public 
health sector is dubious. Unfortunately, the ketamine issue is not an 
isolated one. Several essential medicines used in surgical patient care 
and critical care settings in SA are frequently out of stock or in short 
supply. This article aims to start the conversation and the thinking 
about identifying reasons for the shortages and finding solutions 
to this problem to ensure that we have a plan B. The solution will 
require a multidisciplinary effort from each level of the healthcare 
system (districts, province and the National Department of Health). 
Failure to address the ketamine shortage before stocks are completely 
depleted will have far-reaching effects across our healthcare system.
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